Skip to main content
. 2022 Dec 14;17(1):2052–2061. doi: 10.1515/med-2022-0541

Figure 5.

Figure 5

Dezocine inhibits CRABP2 expression by targeting the Akt/mTOR signaling pathway. (a–c) Expression of important components involved in the Akt/mTOR signaling pathway in ES-2 and SKOV3 cells that were treated with dezocine and CRABP2 overexpression. (d) The protein expression of CRABP2 in ES-2 and SKOV3 cells treated with BEZ235 (10 nM, a double-effect inhibitor of AKT). **P < 0.01, compared with NC group; ## P < 0.01, compared with Dezocine group.